Skip to content
FORSIDEN
Log ind Opret konto
  • Kategorier
  • Seneste
  • Etiketter
  • Populære
  • Verden
  • Bruger
  • Grupper
Temaer
  • Light
  • Brite
  • Cerulean
  • Cosmo
  • Flatly
  • Journal
  • Litera
  • Lumen
  • Lux
  • Materia
  • Minty
  • Morph
  • Pulse
  • Sandstone
  • Simplex
  • Sketchy
  • Spacelab
  • United
  • Yeti
  • Zephyr
  • Dark
  • Cyborg
  • Darkly
  • Quartz
  • Slate
  • Solar
  • Superhero
  • Vapor

  • Default (No Skin)
  • No Skin
Kollaps
  1. Debatforum
  2. Kategorier
  3. Biotek-snakken
  4. Biotek-snakken — Maj 2024

Biotek-snakken — Maj 2024

Planlagt Fastgjort Låst Flyttet Biotek-snakken
67 Indlæg 1 Posters 0 Visninger
  • Ældste til nyeste
  • Nyeste til ældste
  • Most Votes
Svar
  • Svar som emne
Login for at svare
Denne tråd er blevet slettet. Kun brugere med emne behandlings privilegier kan se den.
  • P Offline
    P Offline
    ProinvestorNEWS
    wrote on sidst redigeret af
    #25

    Bioportos omsætningsfremgang drevet af stærk vækst for NGAL-test i USA https://www.proinvestor.com/investornyt/1156584/bioportos-omsaetningsfremgang-drevet-af-staerk-vaekst-for-ngal-test-i-usa

    1 Reply Last reply
    0
    • exitnuE Offline
      exitnuE Offline
      exitnu
      wrote on sidst redigeret af
      #26

      XBRANE AND STADA PARTNER WITH VALORUM BIOLOGICS TO COMMERCIALIZE RANIBIZUMAB BIOSIMILAR CANDIDATE IN THE US

      Link Preview Image
      » Xbrane and STADA partner with Valorum Biologics to commercialize ranibizumab biosimilar candidate in the USXbrane and STADA partner with Valorum Biologics to commercialize ranibizumab biosimilar candidate in the US – Xbrane

      favicon

      (xbrane.com)

      1 Reply Last reply
      0
      • K Offline
        K Offline
        Kjølstad
        wrote on sidst redigeret af
        #27

        IRLAB: Dejlig dag. Regnskabet og perspektiverne belønnes ?

        1 Reply Last reply
        0
        • K Offline
          K Offline
          Kjølstad
          wrote on sidst redigeret af
          #28

          ADMA: Ligeledes i festlig stemning .... og jeg fejrer dagen med mojito på terrassen:-)

          1 Reply Last reply
          0
          • F Offline
            F Offline
            Fandel
            wrote on sidst redigeret af
            #29

            Godmorgen...

            1 Reply Last reply
            0
            • P Offline
              P Offline
              ProinvestorNEWS
              wrote on sidst redigeret af
              #30

              Photocure : Asieris' NDA For Cevira Accepted By NMPA For Regulatory Review In China https://www.proinvestor.com/investornyt/1158788/photocure-asieris-nda-for-cevira-accepted-by-nmpa-for-regulatory-review-in-china

              1 Reply Last reply
              0
              • L Offline
                L Offline
                LP90
                wrote on sidst redigeret af
                #31

                God nyhed med Photocure når man nu har lidt for mange af dem også 🙂

                1 Reply Last reply
                0
                • F Offline
                  F Offline
                  Fandel
                  wrote on sidst redigeret af
                  #32

                  Godmorgen...

                  1 Reply Last reply
                  0
                  • L Offline
                    L Offline
                    LP90
                    wrote on sidst redigeret af
                    #33

                    Godmorgen 🙂

                    1 Reply Last reply
                    0
                    • exitnuE Offline
                      exitnuE Offline
                      exitnu
                      wrote on sidst redigeret af
                      #34

                      Calliditas’ Partner Everest Medicines Starts Commercial Launch of Nefecon in China

                      Link Preview Image
                      Calliditas Therapeutics AB

                      Calliditas is a commercial stage biopharmaceutical company focused on identifying, developing and commercializing novel treatments in orphan indications, with an initial focus on renal and hepatic diseases with significant unmet medical needs.

                      favicon

                      Calliditas Therapeutics AB (www.calliditas.se)

                      1 Reply Last reply
                      0
                      • exitnuE Offline
                        exitnuE Offline
                        exitnu
                        wrote on sidst redigeret af
                        #35

                        “This is a fantastic result from many years of dedication and hard work by teams from both companies and I am delighted that patients in China now can benefit from Nefecon, which has been specifically designed to address the origin of IgAN,” said Renee Aguiar-Lucander, CEO.

                        1 Reply Last reply
                        0
                        • F Offline
                          F Offline
                          Fandel
                          wrote on sidst redigeret af
                          #36

                          Godmorgen...

                          1 Reply Last reply
                          0
                          • L Offline
                            L Offline
                            LP90
                            wrote on sidst redigeret af
                            #37

                            Morning 🙂

                            1 Reply Last reply
                            0
                            • exitnuE Offline
                              exitnuE Offline
                              exitnu
                              wrote on sidst redigeret af
                              #38

                              Genovis - Interim Report January – March 2024

                              https://mb.cision.com/Main/1712/3976051/2798815.pdf

                              "Best quarter for enzyme business in analytics and stronger cash position"

                              1 Reply Last reply
                              0
                              • F Offline
                                F Offline
                                Fandel
                                wrote on sidst redigeret af
                                #39

                                Godmorgen...

                                1 Reply Last reply
                                0
                                • L Offline
                                  L Offline
                                  LP90
                                  wrote on sidst redigeret af
                                  #40

                                  Morning 🙂

                                  1 Reply Last reply
                                  0
                                  • F Offline
                                    F Offline
                                    Fandel
                                    wrote on sidst redigeret af
                                    #41

                                    Godmorgen...

                                    1 Reply Last reply
                                    0
                                    • L Offline
                                      L Offline
                                      LP90
                                      wrote on sidst redigeret af
                                      #42

                                      Godmorgen 🙂

                                      1 Reply Last reply
                                      0
                                      • D Offline
                                        D Offline
                                        DECIDE
                                        wrote on sidst redigeret af
                                        #43

                                        Nanexa ser interessant ud.

                                        1 Reply Last reply
                                        0
                                        • D Offline
                                          D Offline
                                          DECIDE
                                          wrote on sidst redigeret af
                                          #44

                                          Deres PharmaShell teknologi kunne være godt bud på Long acting injectables for en række lægemidler. Har projekt med liraglutid. Desuden muligt partnerskab med Novo Nordisk, mon ikke glp1/sema, men undisclosed Her ligger upside især og Novo skal snart beslutte, om de vil indgå licensaftale. Lav marketcap., høj
                                          risiko, stor upside.

                                          1 Reply Last reply
                                          0

                                          Hello! It looks like you're interested in this conversation, but you don't have an account yet.

                                          Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.

                                          With your input, this post could be even better 💗

                                          Tilmeld Log ind
                                          Svar
                                          • Svar som emne
                                          Login for at svare
                                          • Ældste til nyeste
                                          • Nyeste til ældste
                                          • Most Votes


                                          • Log ind

                                          • Har du ikke en konto? Tilmeld

                                          • Login or register to search.
                                          Powered by NodeBB Contributors
                                          • First post
                                            Last post
                                          0
                                          • Kategorier
                                          • Seneste
                                          • Etiketter
                                          • Populære
                                          • Verden
                                          • Bruger
                                          • Grupper